Jump to content

EGFR: Adjuvant Tagrisso (Osimertinib) news!


Recommended Posts

Great results from ADAURA Phase III trial (Tagrisso for adjuvant use following full resection with negative margins). Mainly: ~3 in 4 patients treated with adjuvant Tagrisso were alive and disease-free at 4 years. Tagrisso also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease.

"Tagrisso demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer": https://www.astrazeneca.com/media-centre/press-releases/2022/tagrisso-demonstrated-5-year-median-disease-free-survival-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.html#!

Other reports on same:

https://www.yalecancercenter.org/news-article/adaura-trial-results-provide-new-hope-for-patients-with-early-stage-non-small-cell-lung-cancer/

https://www.onclive.com/view/updated-adaura-data-reinforce-adjuvant-osimertinib-as-soc-for-egfr-mutated-stage-ib-iiia-nsclc

Hurrah!

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.